READ WHAT OUR EXPERTS RECOMMEND
Read the webinar speakers’ blogs to learn more about the webinar content and submit your comments.
Click here to register and access this Worldwide Diabetes Virtual Webinar endorsed by Primary Care Diabetes Europe.
Click here to download the Worldwide Diabetes Virtual Webinar Flyer.
Jean Claude Mbanya, MD, PhD, MRCP (Program Chair)
Professor of Medicine and Endocrinology and Postgraduate Dean
Faculty of Medicine and Biomedical Sciences
University of Yaoundé I
Jean Claude Mbanya is Consultant Physician and Postgraduate Dean of the Doctoral School of Life, Health and Environmental Sciences at the University of Yaoundé 1 and Dean of the College of Biological Sciences of the Cameroon Academy of Sciences. He is also Chief of Endocrinology and Metabolic Diseases Unit and Director of the National Obesity Centre at the Central Hospital in Yaoundé, Cameroon.
Professor Mbanya initially studied in Cameroon where he obtained his MD in 1979 before continuing his training at the University of Newcastle upon Tyne, England, where he obtained a PhD and eventually MRCP (UK). He is Fellow of the Royal College of Physicians, London, Fellow of the World Academy of Sciences, Trieste, and received a Doctor philosophiae honoris causa from the University of Oslo in 2011 for his outstanding international leadership in the field of diabetes. He is also the recipient of the American Diabetes Association 2004 Harold Rifkin award for Distinguished International Service in the Cause of Diabetes and the 2009 Philip Sherlock Award of the University Outreach Diabetes Group, Jamaica, for his outstanding international service in the field of diabetes.
Professor Mbanya is currently Honorary President of the International Diabetes Federation after serving as President from 2009-2012 and was instrumental in the international advocacy efforts for diabetes and non-communicable diseases (NCDs) at the United Nations, which led to the passage of the United Nations Resolution on Diabetes in 2006 and the UN Political Declaration on NCDs in 2011. Professor Mbanya has authored several books and book chapters and has published over 240 papers in peer-reviewed journals. He is a member of several World Health Organization advisory and expert groups.
Simon Heller, MD
Professor of Clinical Diabetes
University of Sheffield
Director of Research and Development and Honorary Consultant Physician
Sheffield Teaching Hospitals Foundation Trust
Sheffield, England, United Kingdom
Simon Heller is Professor of Clinical Diabetes at the University of Sheffield, Director of Research and Development and Honorary Consultant Physician at Sheffield Teaching Hospitals Foundation Trust. He received his clinical diabetes training at Queen’s Medical Centre, Nottingham, and his research training at the University of Nottingham, Nottingham, England, United Kingdom, and Washington University, St Louis, Missouri, United States. From 2000–2005 he was editor of Diabetic Medicine.
Dr. Heller is currently a member of the Diabetes UK Research Committee, the Diabetes UK Science and Research Advisory Group, at the National Institute for Health Research (NIHR) Health Technology Assessment Panel, and the Juvenile Diabetes Research Foundation, UK Scientific Advisory Committee. Since 2005 he has chaired the Clinical Studies Advisory Group of the Diabetes Research Network in the United Kingdom. He is also an NIHR Senior Investigator.
Dr. Heller’s current research interests include the pathophysiology of hypoglycaemia in diabetes, the contribution of hypoglycaemia to the increased risk of sudden death in young people with type 1 diabetes, the clinical benefits of insulin analogues and trials of complex interventions to enable more effective self-management in people with diabetes. He also leads a group exploring the benefit of insulin pump therapy in a randomized controlled trial (REPOSE) among adults with type 1 diabetes. He has authored more than 150 original research articles and reviews in both national and international publications. Dr. Heller was a co-investigator, member of the Management Committee, and Chair of the Glucose control group in the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE ) Trial. He is a member of the Steering Committee for the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) Trial.
Paolo Pozzilli, MD
Professor of Endocrinology and Metabolism
University Campus BioMedico
Professor of Diabetes and Clinical Research
Blizard Institute, St. Bartholomew’s and the London School of Medicine
Queen Mary University of London
London, England, United Kingdom
Paolo Pozzilli is Professor of Endocrinology and Metabolism at University Campus BioMedico in Rome where he is Director of the Unit of Endocrinology & Diabetes and of the Postgraduate School of Endocrinology & Metabolic Diseases. He is the coordinator of the PhD Program in Integrated Biomedical Sciences and Bioethics. He is also Professor of Diabetes and Clinical Research at the Blizard Institute, St. Bartholomew’s and the London School of Medicine, Queen Mary University of London. Recently, he was Visiting Professor at the Joslin Diabetes Center in Boston, Harvard University.
Dr. Pozzilli’s main research activities include the study of the pathogenesis of type 1 diabetes and its complications, the introduction of novel treatments and the application of technology to the management of diabetes. He participated in the design of algorithms for treatment of type 2 diabetes and has been principal investigator for more than 50 clinical trials in diabetes. Most recent trials include Roadmap, In Tandem-2, Exscel and Canvas, all published in the New England Journal of Medicine. His recent projects have focused on antidiabetic therapies including SGLT-2s, GLP-1s, novel forms of insulin and novel technology applied to diabetes care. For his research, Dr. Pozzilli is funded at present by the Juvenile Diabetes Research Foundation (USA), the EFSD Foundation, the Italian Ministry of University and the Italian Ministry of Health. His international reputation established over 30 years of diabetes research is reflected in special lectures given at the American Diabetes Association, the European Association for the Study of Diabetes (EASD), the International Diabetes Federation, organizing and chairing 18 international symposia on the occasion of the EASD congresses and 22 Bart’s International Symposia in London since 1996. He was among the first to describe cell-mediated immune reactivity in type 1 diabetes and championed the concept of immunotherapy in this disease by carrying out 14 IMDIAB trials (see IMDIAB on Pubmed).
Dr. Pozzili pioneered the description of double diabetes, that is, type 1 and type 2 diabetes occurring in the same subject. He is the recipient of several awards including among others, the Andrew Cudworth Memorial Award from Diabetes UK, the GB Morgagni Young Investigator Award from the Society of Metabolism, the Marie Kugel Award from the Juvenile Diabetes Research Foundation International, the Celso Prize from the Italian Diabetes Society and the Joseph Hoet Memorial Award for his contribution to the field of type 1 diabetes prevention. Currently Editor of Diabetes Metabolism Research & Review, he has published 470 papers (Pubmed) in the area of diabetes and related fields.
Sanjay Rajagopalan, MD, FACC, FAHA
Chief, Division of Cardiovascular Medicine
University Hospitals, Harrington Heart and Vascular Institute (HHVI)
Director, Case Cardiovascular Research Institute
Herman K. Hellerstein MD, Professor of Cardiovascular Research
Professor, Department of Internal Medicine and Radiology
Case Western Reserve University
Cleveland, Ohio, USA
Sanjay Rajagopalan is Professor of the Department of Medicine and Director of the Cardiovascular Research Institute at Case Western Reserve University School of Medicine in Cleveland, Ohio. He completed clinical and research fellowships in cardiovascular medicine and vascular biology at the Emory University School of Medicine, Atlanta, Georgia, and is among an elite group of physician investigators whose work has help transform perceptions and facilitate understanding of the global impact of chronic diseases including diabetes. In addition, Dr. Rajagopalan has made seminal contributions towards the development of next generation therapeutic modalities for the treatment of cardiovascular disease and is a leading authority in advancing newer and innovative non-invasive approaches for the diagnosis of complex cardiovascular disorders.
Dr. Rajagopalan’s laboratory has been continually funded by the National Institutes of Health (NIH). Dr. Rajagopalan is an elected member of the American Society of Clinical Investigation (ASCI), the Association of University Cardiologists (AUC) and the Association of Professors of Cardiology (APC). Additional honors include the William Keating Award from the American College of Cardiology, the Charles Dana Award and being voted amongst the Best Doctors in America.
Dr. Rajagopalan has published more than 300 original peer reviewed research publications in journals such as JAMA, New England Journal of Medicine, Circulation, Journal of Clinical Investigation and Circulation Research, in addition to more than 300 reviews, book chapters and abstracts. He has served as an editor for at least two textbooks and several monographs on vascular disease and atherosclerosis.
The virtual webinar is sponsored by the Worldwide Initiative for Diabetes Education and supported by an educational grant from Novo Nordisk A/S.